The clinical viewpoint: Definitions, limitations of RECIST, practical considerations of measurement

Clinical Cancer Research

Volumn 19, Issue 10, 2013, Pages 2629-2636

  Villaruz, Liza C ^a   Socinski, Mark A ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; CISPLATIN DERIVATIVE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IPILIMUMAB; MONOCLONAL ANTIBODY; PEMETREXED; VANDETANIB; VASCULOTROPIN;

CANCER RECURRENCE; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; INFORMATION PROCESSING; INTERMETHOD COMPARISON; INTERNAL BIAS; LUNG NON SMALL CELL CANCER; METASTASIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SAMPLE SIZE; SENSITIVITY ANALYSIS; SOLID TUMOR; STUDY DESIGN; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; VALIDITY; BIOASSAY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; NEOPLASMS; PATHOLOGY; PROCEDURES; REPRODUCIBILITY;

CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS;

EID: 84878095934     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2935     Document Type: Review

References (35)

1. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 1976;38: 388-94.
2. Fojo T, Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res 2010; 16:5972-80.
3. Wilkerson J, Fojo T. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival. Cancer J 2009;15:379-85.
4. U.S. Food and Drug Administration. Guidance for industry. Clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: U.S. Department of Health and Human Services; 2007.
5. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
6. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
7. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15: 257-60.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
9. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15: 7412-20.
10. Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28:911-7.
11. Sridhara R, Mandrekar SJ, Dodd LE. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. Clin Cancer Res 2013;19:2613-20.
12. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced nonsmall-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-31.
13. Zhang JJ, Zhang L, Chen H, Murgo A, Dodd LE, Pazdur R. Evaluation of audit methodologies for tumor progression in oncology clinical trials. Clin Cancer Res 2013;19:2637-45.
14. Panageas KS, Ben-Porat L, Dickler MN, Chapman PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007;99:428-32.
15. Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, et al. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer 2012;118:5358-65.
16. Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM Jr, et al. Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol 2010;5:3-9.
17. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
18. Buyse M, Squifflet P, Laporte S, Fossella F, Georgoulias V, Pujol J, et al. Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: evidence from a pooled analysis of 2,838 patients randomized in 7 trials. J Clin Oncol 26:15s, 2008 (suppl; abstr 8019).
19. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011;117:1262-71.
20. Lara PN Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008; 26:463-7.
21. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
22. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
23. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-46.
24. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74.
25. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
26. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
27. Jotte R, Von Pawel J, Spigel DR, Socinski MA, O'Brien M, Paschold E, et al. Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). J Clin Oncol 29:15s, 2011 (suppl; abstr 7000).
28. Amir E, Seruga B, Kwong R, Tannock IF, Ocana A. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer 2012;48: 385-8.
29. Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11: 619-26.
30. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
31. Kay A, Higgins J, Day AG, Meyer RM, Booth CM. Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points. Ann Oncol 2012;23:1646-51.
32. Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst 2010;102:230-43.
33. U.S. Food and Drug Administration. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. [cited 2011]. Available from: http://www.fda.gov/NewsEvents/Newsroom/Press-Announcements/ucm269856.htm.
34. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12: 1004-12.
35. Shaw AT. Phase III randomized study of crizotinib versus pemetrexed or docetaxel chemotherapy in advanced, ALK-positive non-small cell lung cancer (NSCLC) [abstract]. In: Proceedings of the ESMO 2012 Congress; 2012; Vienna, Austria. Abstract #LBA1.